PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial

James P Buteau,Andrew J Martin,Louise Emmett,Amir Iravani,Shahneen Sandhu,Anthony M Joshua,Roslyn J Francis,Alison Y Zhang,Andrew M Scott,Sze-Ting Lee,Arun A Azad,Margaret M McJannett,Martin R Stockler,Scott G Williams,Ian D Davis,Michael S Hofman,Tim Akhurst,Ramin Alipour,Arun A Azad,Patricia Banks,Alexis Beaulieu,James P Buteau,Wei Chua,Ian D Davis,Nattakorn Dhiantravan,Louise Emmett,Kate Ford,Michael S Hofman,Roslyn J Francis,Craig Gedye,Jeffrey C Goh,Alex Guminski,Anis Hamid,Mohammad B Haskali,Rodney J Hicks,Edward Hsiao,Amir Iravani,Anthony M Joshua,Ian D Kirkwood,Grace Kong,Edmond M Kwan,Ailsa Langford,Nicola Lawrence,Sze-Ting Lee,Jeremy Lewin,Peter Lin,Andrew J Martin, William McDonald,Margaret M McJannett,Kate Moodie,Declan G Murphy,Siobhan Ng,David A Pattison,Izabella Pokorski,Shakher Ramdave,Aravind S Ravi Kumar,Andrew D Redfern,Natalie K Rutherford, Javad Saghebi,Shahneen Sandhu,Andrew M Scott,Lavinia Spain,Martin R Stockler,Shalini Subramaniam,Thean Hsiang Tan,Sue Ping Thang,Ben Tran,Roslyn Wallace,Andrew Weickhardt,Scott G Williams,Sonia Yip,Alison Y Zhang

The Lancet Oncology（2022）

引用 46|浏览9

暂无评分

摘要

Prostate Cancer Foundation of Australia, Endocyte (a Novartis Company), Australian Nuclear Science and Technology Organisation, Movember Foundation, It's a Bloke Thing, CAN4CANCER, The Distinguished Gentleman's Ride.

查看译文

关键词

prostate cancer,prognostic biomarkers,biomarkers analysis,fdg-pet,lu]lu-psma,castration-resistant,open-label

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要